Medical Insights
Cardiac AI: Why Post-Market Surveillance is Your Next Big Bet
Cardiac AI validation does not conclude at regulatory clearance. Post-market surveillance systems track performance after deployment.…
Medical Insights
Cardiac AI validation does not conclude at regulatory clearance. Post-market surveillance systems track performance after deployment.…
Medical Insights
Cardiac AI monitoring diagnostics market claims require rigorous validation. The Mount Sinai/Nature Medicine finding that ChatGPT…
Medical Insights
Theranos, Olive AI, and iRhythm Technologies represent a recorded set of diagnostic, automation, and ambulatory heart…
Medical Insights
Cardiac AI programs produce outcomes. The legibility of these outcomes across diverse populations presents a critical…
Medical Insights
Cardiac AI monitoring diagnostics market claims often outpace measured accuracy. A 48% undertriage rate for cardiac…
Medical Insights
De Novo Classification defines a regulatory pathway for novel medical devices. This classification establishes an evidence…
Medical Insights
When the Mount Sinai/Nature Medicine finding reported that ChatGPT undertriaged cardiac emergencies in 48% of cases,…
Medical Insights
Clinicians verify AI output at the point of use. This human read acts as a critical…
Medical Insights
Cardiac AI validation evidence provides the practical foundation for review teams. This evidence includes recorded materials…
Medical Insights
When the FDA sent Theranos that warning letter in 2015, it wasn’t just a slap on…